ArticleDiscover oncology2025
Serum miR-200c-3p and miR-6134 as diagnostic biomarkers for epithelial ovarian cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Differential Serum MicroRNA Profiling in Benign and Malignant Ovarian Tumours: An Exploratory Study Identifying hsa-miR-200c-3p as a Candidate Diagnostic Biomarker.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMicroRNAs (miRNAs) regulate gene expression and are emerging as biomarkers for epithelial ovarian cancer (EOC). We evaluated the diagnostic performance of serum miR-200c-3p and miR-6134, alone and in combination with established markers, to distinguish EOC from benign ovarian tumors and healthy controls.
methodsIn this single-center, retrospective study, sera were collected from patients with EOC (N = 95), benign tumors (N = 115), and healthy controls (N = 40). Candidate miRNAs were screened by microarray and quantified by real-time PCR. Serum CA125, HE4, and IL-6 were measured by ELISA. Receiver operating characteristic curves and area under the curve (AUC) values were used to assess diagnostic performance.
resultsBoth miR-200c-3p and miR-6134 were significantly upregulated in EOC. In EOC vs. healthy controls, HE4 showed the highest AUC (0.929, 95% confidence interval [CI]: 0.886-0.972), followed by CA125 (0.870, CI: 0.807-0.933) and miR-6134 (0.818,CI: 0.749-0.888). In EOC vs. benign tumors, miR-6134 had the highest AUC (0.933,CI: 0.891-0.975). The combination of miR-6134, CA125, HE4, and IL-6 achieved an AUC of 0.968 (CI: 0.942-0.995). Among patients with CA125 < 35 U/mL, the combination of miR-200c-3p and miR-6134 yielded an AUC of 0.935 (CI: 0.848-1.000).
conclusionsThe combination of miR-6134, CA125, HE4, and IL-6, or miR-6134 alone, shows potential as a serum biomarker for EOC, particularly in distinguishing malignant from benign ovarian tumors. The combination of two miRNAs also demonstrated high discriminative power in cases with CA125 below the cutoff. These findings may contribute to the development of improved non-invasive diagnostic tools and warrant further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.